4月27日，5G AI智能射频技术探讨会暨YOUMAGIC高能单极射频公立医院全国首发仪式"在重庆医科大 学附属大学城医院隆重举行。此次会议标志着YOUMAGIC高能单极射频技术正式进入全国公立医院体 系，开启智能射频技术在临床科研与医疗创新领域的深度应用，将以创新射频科技实力助力公立医院的 高质量创新发展。 重庆医科大学附属大学城医院党委委员、副院长唐博在致辞中表示，YOUMAGIC高能单极射频技术由 清华大学工物系创新研发，可作用于面部真皮层及以下，能有效减轻面部轻中度皱纹。凭借其自主创新 优势，为射频抗衰领域提供了全新的技术选择。YOUMAGIC的引进不仅将推动医院临床治疗水平的提 升，更能让广大患者体验到高能射频科技带来的精准抗衰效果与更舒适的优质医疗服务，进一步满足日 益增长的高品质医疗需求。 随后，重庆市中医院皮肤科主任中医师薛梅，重庆市中医院皮肤美容科亚专业组组长、副主任医师苏 戈，重庆医科大学附属大学城医院皮肤科学科带头人、主任医师柯丹等分别致辞表示对YOUMAGIC高 能单极射频的进院期待，将充分利用这一创新设备开展临床科研，为患者带来更优质更舒适的紧肤服 务。威脉医疗创始人兼CEO李天民表 ...

Group 1: Economic Indicators - As of the end of March, Jiangsu's RMB loan balance increased by 10.7%, indicating strong economic resilience and potential [1] - By the end of March, 162 out of 274 planned major projects in the province had commenced, exceeding the target of 40% for the first quarter [2] - The province's major projects completed an investment of 175 billion yuan, achieving a completion rate of 26.8%, which is 1.8 percentage points higher than the scheduled progress [2] Group 2: Private Sector Investment - Jiangsu's private enterprises showed significant growth, with the industrial added value of large-scale private enterprises increasing by 10%, outperforming the overall industrial growth by 1.8 percentage points [4] - In the first two months, the profit of large-scale private industrial enterprises reached 46.92 billion yuan, a year-on-year increase of 11% [4] - The total public loan balance of Nanjing Bank surpassed 1 trillion yuan for the first time, with an increase of 8.75% since the beginning of the year [4] Group 3: Financial Support and Policy Environment - The financial environment has been bolstered by a "certain commitment" from policies, with a total financing demand of 309.8 billion yuan for 418 major projects announced [3] - The province has introduced a suite of financial tools, including the first credit loan product specifically for private enterprises [5] - The strategic emerging industry fund has been established with a scale of 40.8 billion yuan, focusing on key industries such as new materials and green low-carbon sectors [5] Group 4: Consumer Market Recovery - The recovery of the consumer market is a significant driver for the increase in loan balances, supported by new housing policies in Nanjing that have stimulated real estate transactions [6] - In March, Nanjing introduced seven policy measures to stabilize the real estate market, including the cancellation of sales restrictions [6] - The sales of new energy vehicles in Jiangsu increased by 29.2% year-on-year in the first quarter, contributing to a 2.1% growth in retail sales [7]

Core Insights - Hologic (HOLX) is expected to report quarterly earnings of $1.02 per share, reflecting a year-over-year decline of 1% and revenues of $1 billion, which is a 1.6% decrease compared to the previous year [1] - The consensus EPS estimate has been adjusted downward by 0.1% over the past 30 days, indicating a reassessment by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Estimates - Analysts project 'Revenues- Diagnostics- Cytology and Perinatal' at $119.94 million, a decrease of 0.5% year-over-year [5] - 'Revenues- Diagnostics- Molecular Diagnostics' is estimated to be $328.58 million, reflecting an increase of 1.8% from the prior year [5] - 'Revenues- Diagnostics- Blood Screening' is expected to reach $4.99 million, indicating a significant decline of 27.6% [6] - 'Revenues- Breast Health- Breast Imaging' is projected at $282.58 million, down 7.9% from the previous year [6] - 'Revenue- Skeletal Health' is estimated at $18.00 million, showing a decline of 33.6% [6] - Total Breast Health revenue is expected to be $369.50 million, a decrease of 3.9% year-over-year [7] - Total Diagnostics revenue is projected at $453.52 million, reflecting a slight increase of 0.8% [7] - 'Revenue- GYN Surgical' is estimated to reach $161.11 million, indicating a growth of 3.3% [7] - 'Revenues- Breast Health- Interventional Breast Solutions' is expected to be $86.91 million, showing an increase of 11.6% from the prior year [8] Stock Performance - Over the past month, Hologic shares have declined by 5.4%, compared to a 4.3% decline in the Zacks S&P 500 composite [8] - Hologic holds a Zacks Rank 3 (Hold), suggesting that its performance is likely to align with the overall market in the near term [8]

Financial Performance - In Q1 2025, the company achieved a revenue of 420 million CNY, a decrease of approximately 5% year-on-year [3] - Domestic sales revenue was 166 million CNY, down about 20% year-on-year, while international sales revenue was 254 million CNY, up approximately 7% [3] - The overall gross margin for 2024 reached 57.92%, showing an improvement due to an increase in high-margin product sales [8] Market Outlook - The company maintains an optimistic outlook for domestic sales growth in 2025, anticipating recovery in market demand and the introduction of competitive new products [3] - The overseas patient monitoring business is expected to grow at a double-digit rate, with positive performance in Q1 2025 [11] AI Integration - The company established an AI-focused organization in March 2025, aiming to enhance efficiency and create value in ultrasound imaging and smart healthcare [4] - AI applications have significantly reduced examination times and improved patient flow management in emergency settings [4] Supply Chain and Tariff Impact - Components imported from the U.S. account for approximately 0-10% of the main product costs, with ongoing adjustments to ensure supply chain stability amid tariff uncertainties [9] - The company has initiated capacity expansion for its U.S. subsidiary to mitigate the impact of increased tariffs, with completion expected by June 2025 [7] Product Development and Strategy - The i500 wet blood gas product has been cautiously promoted since Q4 2024, with a focus on long-term market leadership and customer satisfaction [12] - The company is actively monitoring the impact of price reductions in IVD products due to centralized procurement policies, which have limited effects on its business [14] Inventory Management - By the second half of 2024, domestic channel inventory levels have returned to normal, allowing for a more stable sales environment [13] - The company has optimized its internal sales team to enhance competitiveness in the domestic market [7] Health Care Product Promotion - The domestic market strategy for personal health care products includes leveraging e-commerce platforms and extending the company's strong brand influence in obstetrics [15]

Core Viewpoint - The China Securities Index for the medical industry has shown a decline in performance over various time frames, indicating potential challenges within the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry has decreased by 5.99% over the past month, 1.12% over the past three months, and 6.26% year-to-date [2]. - The index was established with a base date of December 31, 2021, set at 1000.0 points [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.15%) - Aier Eye Hospital (9.35%) - United Imaging (8.03%) - Aimeike (4.1%) - Huatai Medical (3.87%) - New Industry (3.16%) - Shanghai Pharmaceuticals (3.11%) - Yuyue Medical (3.06%) - Yifeng Pharmacy (2.49%) - Meinian Onehealth (2.45%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (56.76%) and the Shanghai Stock Exchange (43.24%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.77% - Medical Consumables: 22.92% - Pharmaceutical Commerce: 15.73% - Medical Services: 14.44% - In Vitro Diagnostics: 12.14% [2]. Group 4: Sample Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Devices shows a recent decline, but has experienced significant growth over the past three months and year-to-date [1]. Group 1: Index Performance - The China Securities Index for Hong Kong Stock Connect Medical Devices reported a recent value of 1194.94 points [1]. - Over the past month, the index has decreased by 3.48%, while it has increased by 15.43% over the last three months and 12.63% year-to-date [1]. Group 2: Index Composition - The index is composed entirely of securities listed on the Hong Kong Stock Exchange, with a sample that includes various sectors classified under the China Securities Industry Classification Standard [2]. - The index's sample shows that medical consumables account for 79.10%, medical devices for 16.57%, and in vitro diagnostics for 4.34% [2]. Group 3: Index Adjustments - The index samples are adjusted biannually, specifically on the second Friday of June and December, with weight factors fixed until the next scheduled adjustment [2]. - In cases of special events affecting the index sample, such as delisting or mergers, adjustments will be made accordingly [2].

Core Viewpoint - Xi'an Dayi Group Co., Ltd. has submitted an application to the Hong Kong Stock Exchange, with CITIC Securities International, Pudong Development Bank International, and Minyin Capital as joint sponsors [1] Company Overview - Dayi Group is a global leader in innovative radiosurgery solutions, aiming to build a next-generation intelligent radiosurgery ecosystem since its establishment in 2011 [3] - The core product, CybeRay, is the world's first real-time image-guided gamma radiosurgery system, approved by the FDA in March 2021 and by the National Medical Products Administration of China in July 2022, currently in the research phase for expanding indications [3] - Another flagship product, TaiChiRT Pro, is the first integrated X/gamma-ray radiosurgery system to receive breakthrough medical device designation from the FDA [3] Market Potential - The current focus of radiosurgery is on tumor treatment, but potential applications are expanding into non-tumor indications [4] - The global market size for radiosurgery is projected to grow from $92.4 billion in 2024 to $138.9 billion by 2030, with a compound annual growth rate (CAGR) of 7.0% [4] - In China, the tumor radiotherapy market is expected to increase from RMB 59.4 billion to RMB 105.8 billion, with a CAGR of 10.1% [4] - The U.S. tumor radiotherapy market is estimated to grow from $50.3 billion to $68.0 billion, with a CAGR of 5.2% [4] Technological Advancements - Dayi Group is transitioning treatment modalities from traditional invasive and minimally invasive surgeries to non-invasive procedures, ensuring patient health while delivering breakthrough clinical outcomes [4] - The company integrates various radiation therapy technologies, multi-ray imaging techniques, intelligent software platforms, and smart algorithms to create a precise radiosurgery treatment system covering both tumor and non-tumor indications [4][6] Financial Performance - For the fiscal years 2023 and 2024, Dayi Group's revenue is projected to be approximately RMB 261 million and RMB 264 million, respectively [6] - The company anticipates losses of approximately RMB 69.78 million in 2023 and RMB 94.57 million in 2024 [6][7] - The financial data indicates a gross profit of RMB 128.17 million in 2023, increasing to RMB 138.82 million in 2024 [7]

Macro Strategy and North Exchange - The macro policy remains stable with LPR unchanged at 3.10% for 1-year and 3.60% for 5-year [5] - Industrial enterprise profits showed a year-on-year increase of 2.60% in March, marking the first positive growth since the previous year [5] - The Central Political Bureau emphasized the need for high-quality development to address international economic and trade struggles, focusing on "Four Stabilities" [7][8] - The government plans to accelerate the issuance of special bonds and long-term bonds, with a deficit rate set at around 4% and a total deficit scale of 5.66 trillion yuan, an increase of 1.6 trillion yuan from 2024 [8] - Monetary policy will include timely reductions in reserve requirements and interest rates, along with new structural monetary policy tools to support innovation and consumption [10][11] A-Share Market Overview - From April 21 to April 27, 2025, most A-share indices rose, with the Shanghai Composite Index increasing by 0.56% and the Shenzhen Component Index by 1.38% [15] - The market is expected to maintain a narrow fluctuation state due to the recent "reciprocal tariffs" imposed by the US and the upcoming May Day holiday [15][23] - The report indicates a "slow bull" market trend for A-shares in 2025, with a focus on technology, green energy, consumption, and infrastructure sectors [23] North Exchange Market Overview - As of April 25, 2025, the North Exchange had 265 listed stocks, with an average total market value of 755.47 billion yuan, an increase of 1.53% from the previous week [24] - The liquidity in the North Exchange decreased, with average trading volume dropping by 9.79% to 1.384 billion shares [25] - The North Exchange's 50 Index closed at 1300.19 points, down 2.16% from the previous week [26] Industry Insights: Food and Beverage - Salted Fish reported a revenue of 5.304 billion yuan and a net profit of 640 million yuan for 2024, reflecting a year-on-year increase of 28.89% and 26.53% respectively [34] - The company is focusing on core product categories with strong growth, particularly in spicy snacks and baked goods, with significant revenue increases [35] - Salted Fish is accelerating its overseas expansion, with a projected revenue of 6.678 billion yuan in 2025, growing at 25.9% year-on-year [38] Industry Insights: Medical Devices - The sales of ultrasound imaging devices showed a significant recovery in Q1 2025, with sales revenue increasing by 87.95% year-on-year [40] - The report highlights a shift towards domestic brands, with domestic sales accounting for 37.79% of the market share in 2024, up from 34.20% in 2023 [42] - The report suggests a positive outlook for domestic ultrasound device manufacturers like Mindray and KAILI Medical, as the market for these devices is expected to continue recovering [48]

Core Insights - 2025 is a pivotal year for the medical equipment procurement market, with significant policy initiatives aimed at equipment upgrades and the construction of county-level medical communities driving a surge in procurement activities [1] - The CT procurement market has notably rebounded, with domestic manufacturers like Neusoft Medical achieving substantial sales growth, surpassing competitors like "GPS" [1] Market Performance - The CT market experienced over 90% year-on-year growth in both sales volume and revenue in Q1 2025, driven by policies related to equipment updates and county-level medical community construction [3][4] - In the CT market, 64-slice and below CTs account for over 70% of procurement, while 128-slice and 256-slice CTs represent approximately 11.66% and 16.63% respectively [4] Product Success - Neusoft Medical's NeuViz ACE series has excelled in the county-level medical community procurement market, securing large orders across multiple provinces [6] - NeuViz ACE UP ranked first in sales with a market share of 5.86%, indicating high market acceptance [9] Innovation and R&D - The increasing market acceptance of new products and technologies is evident, with stricter procurement requirements emphasizing AI-assisted diagnostics and advanced software [11] - Neusoft Medical has received 17 CT registration certificates from 2020 to 2025, accounting for 73.19% of the total, significantly outpacing established foreign competitors [12][13] Competitive Landscape - The competition in the medical equipment industry is evolving from product-based to ecosystem-based, with a focus on integrated solutions and smart technologies [15] - Neusoft Medical is leveraging its partnerships and advanced technologies to build a comprehensive ecosystem, enhancing its competitive position in the market [16]

4月23日，由深圳大学总医院整形美容中心、深圳大学中英医美大健康学院及亚太联盟医疗健康学会联 合主办的"深港抗衰学术沙龙暨YOUMAGIC单极射频技术交流会"在深圳大学隆重举行。本次会议聚焦 全球抗衰技术前沿，特别展示了YOUMAGIC单极射频技术的突破性成果，吸引了大湾区抗衰产业和顶 尖医美专家学者的高度关注。 用创新性射频科技促进大湾区医疗美容行业融合发展，深化医工结合研发进程为行业注入发展新活力。 作为本次学术沙龙的核心议题，YOUMAGIC首席科学家于昊博士在会中分享了YOUMAGIC单极射频的 技术原理和研究数据成果，向与会专家全面展示了清华智造如何用创新技术推动高端国产医疗设备的崛 起。 依托清华大学独家功率源技术，YOUMAGIC用高频电磁波刺激真皮层及皮下组织的胶原蛋白再生，实 现皮肤提拉紧致、改善皱纹的效果。在技术升级上，将传统射频200ms脉宽升级为100ms，带来近2倍温 控监测点，让射频温升更稳定，使用体感更安全舒适；在治疗模式上，可根据用户皮肤状态调节长短脉 冲，短脉冲快速累积热量以缩短治疗时间，长脉冲则让升温舒缓，对干敏不耐受肌肤更友好，搭配多重 制冷调节技术、AI能量匹配技术与多 ...